Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

This study tests a new medicine called HDM1005 against an existing drug, mazdutide, in about 900 adults with type 2 diabetes whose blood sugar is not well controlled by metformin alone or with another diabetes pill. The goal is to see which drug works better at lowering blood sug…

This study tests whether adding ganagliflozin tablets to standard treatment can slow kidney disease in people with type 2 diabetes and chronic kidney disease. About 1,244 adults will take either the drug or a placebo for 120 weeks. The main goal is to see if the drug helps preser…

This early-stage study tests a single shot of HDM1005 in 30 people, some with kidney impairment and some healthy. The goal is to see how the drug moves through the body and if it is safe. Results will help guide future dosing for people with kidney issues.

This early-stage study looks at how a new drug called HDM1005 affects stomach emptying and interacts with four common medications (metformin, atorvastatin, warfarin, and digoxin) in 42 overweight or obese Chinese adults aged 18-45. The goal is to understand how the body processes…